12. Axumin

Micrograph of prostate cancer with Gleason pattern—Courtesy of Michael Bonert CC BY-SA 3.0

Active ingredient: fluciclovine F 18
Disease: Recurrent prostate cancer
Peak sales estimate: none available
Approved: May 27
Company: Blue Earth Diagnostics

The Scoop: Blue Earth Diagnostics’ Axumin is a novel molecular imaging agent used in PET imaging to identify suspected sites of recurrent prostate cancer, the first F18 PET imaging agent approved for this use. While the recurrent disease is typically detected by a rise in PSA levels, the location and extent of the disease cannot be detected by conventional imaging and that is where Axumin comes in. It works by targeting the increased amino acid transport that occurs in prostate cancer, and other cancers, that when labeled with the radioisotope F18 will show up on a PET scan. While most primary prostate cancer can be treated successfully, it does recur in up to one-third of patients, and of those, approximately one-third develop metastatic prostate cancer. Prostate cancer is the second leading cause of cancer death in men. Privately owned Oxford, England-based Blue Earth has contracted with Siemens’ PETNET Solutions to be the exclusive distributor in the U.S. —Eric Palmer

12. Axumin

Suggested Articles

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.

The creation of the latest outpost of the BRIDGE model sees Evotec team up with Integra Holdings and Yissum to help researchers at Hebrew University.